Skip to main content
. 2010 Mar 18;5(3):e9750. doi: 10.1371/journal.pone.0009750

Figure 4. hMSC-scFvEGFRvIII extend the survival of U87-EGFRvIII glioma in an intracranial model.

Figure 4

A. U87-EGFRvIII cells alone (1×105) or with equal amount of control or scFvEGFRvIII expressing hMSCs (n = 12 per group) were inoculated in the right hemisphere of athymic mice. Survival of the animals was recorded until last animal died. B. U87-EGFRvIII cells alone (1×105) (n = 13) or with equal amount of control (n = 10) or scFvEGFRvIII expressing hMSCs (n = 11) were inoculated in the right hemisphere of athymic mice. Animals received an additional 3×105 of control or hMSC-scFvEGFRvIII intratumoral inoculation at 2 weeks and the survival of the animals was recorded. C. Microphotograph of 10 µm tissue sections from 4 week brain tumors (i) GFP expressing U87-EGFRvIII cells alone and either (ii) with control hMSC-vector or (iii) hMSC-scFvEGFRvIII cells. Arrows indicate the presence of hMSC expressing RFP.